Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sevoflurane
Drug ID BADD_D02015
Description Sevoflurane, also called fluoromethyl, is an ether inhalation anaesthetic agent used for the induction and maintenance of general anesthesia. It is a volatile, non-flammable, non-irritant, and easy-to-administer compound with a low solubility profile and blood-to-gas partition coefficient.
Indications and Usage Used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
Marketing Status approved; vet_approved
ATC Code N01AB08
DrugBank ID DB01236
KEGG ID D00547
MeSH ID D000077149
PubChem ID 5206
TTD Drug ID D0W6ZF
NDC Product Code 12164-009; 10019-653; 0074-4456; 0781-6160; 66794-012; 54122-4486; 66794-015; 66794-022; 10019-651; 12164-005; 42677-110; 57884-0036; 10019-655; 10019-657
UNII 38LVP0K73A
Synonyms Sevoflurane | Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl Ether | Fluoromethyl Hexafluoroisopropyl Ether | Sevorane | Ultane | BAX 3084
Chemical Information
Molecular Formula C4H3F7O
CAS Registry Number 28523-86-6
SMILES C(OC(C(F)(F)F)C(F)(F)F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertensive crisis24.08.01.0010.000268%Not Available
Hyperthermia12.05.01.002; 08.05.01.0010.000268%Not Available
Hyperthermia malignant08.05.01.0020.002179%Not Available
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypokalaemia14.05.03.0020.000179%
Hypophosphataemia14.04.03.001--
Hypotension24.06.03.0020.000661%
Hypothermia08.05.01.003; 12.05.03.001--
Hypoventilation22.02.01.007--Not Available
Hypoxia22.02.02.0030.000536%
IIIrd nerve paralysis17.04.02.003; 06.05.02.0110.000268%Not Available
Immune system disorder10.02.01.001--Not Available
Influenza like illness08.01.03.0100.000393%
Insomnia19.02.01.002; 17.15.03.002--
Intracranial pressure increased17.07.02.0020.000179%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Lactic acidosis14.01.01.0020.000268%Not Available
Laryngospasm22.04.02.0020.000357%
Lethargy17.02.04.003; 08.01.01.008; 19.04.04.0040.000179%
Leukocytosis01.02.01.002--
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.004--Not Available
Metabolic acidosis14.01.01.0030.000179%Not Available
Muscle rigidity15.05.04.001; 17.05.02.0050.000179%Not Available
Muscle twitching15.05.03.005--Not Available
Mydriasis17.02.11.003; 06.05.03.0040.000447%Not Available
Myocardial infarction24.04.04.009; 02.02.02.0070.000536%
Myoclonus17.02.05.0080.000179%Not Available
Nausea07.01.07.001--
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene